RxDoctor Payments Data

Sindhu Dadlani, MD

Internal Medicine · Zephyrhills, FLNPI 1720038326

Payments from drug & device makers

$549in general payments, 2019–2025

Across 20 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$346
  • Boehringer Ingelheim$70
  • Lilly USA, LLC$31
  • Boston Scientific$31
  • Pharming Healthcare, Inc.$22
  • Otsuka America Pharmaceutical, Inc.$20
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$549 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$32,600
Medicare patients
99
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter160$200,599
JardianceEmpagliflozin158$141,847
EliquisApixaban96$96,419
FarxigaDapagliflozin Propanediol48$54,800
OzempicSemaglutide35$52,498
XareltoRivaroxaban39$44,675
Novolin NInsulin Nph Human Isophane63$15,152
TrulicityDulaglutide12$14,835
InvokanaCanagliflozin20$13,645
MyrbetriqMirabegron11$9,126
Fluticasone-SalmeterolFluticasone Propion/Salmeterol52$8,978
Albuterol Sulfate HfaAlbuterol Sulfate196$7,120
Gabapentin307$6,951
Wixela InhubFluticasone Propion/Salmeterol42$6,458
Levothyroxine Sodium413$5,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$346$205,322172 claims
Boehringer IngelheimJardiance$70$141,847158 claims
AstraZenecaFarxiga$14$54,80048 claims
Lilly USA, LLCTrulicity$31$14,83512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →